Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride 3(2H)-dione hydrochloride InChI Key LQYLHZFKGOZTOH-UHFFFAOYSA-N

3(2H)-dione hydrochloride InChI Key LQYLHZFKGOZTOH-UHFFFAOYSA-N Smiles NCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C3CCC(NC3=O)=O)=O

K02288 causes near complete inhibition of Smad2 phosphorylation at 0

2015 Jan 8

heterobifunctional protein crosslinking reagent that is commonly used to crosslink haptens to carrier proteins and enzymes to antibodies

Smiles: COC1C=C(NC2=NC3=CC=CC=C3N=C2NS(=O)(=O)C2C=C(C=CC=2)NC(=O)C(C)(C)N)C(Cl)=CC=1

Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride 3(2H)-dione hydrochloride InChI Key LQYLHZFKGOZTOH-UHFFFAOYSA-NRivaroxaban, also known as BAY 59 7939, is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 812 hours, but